A Big Pharma company, Insys caught bribing doctors to prescribe opioids and lobbying against pot, just got their second synthetic THC approved by FDA.

The historic Nov. 2016 ballot initiatives to legalize cannabis brought a resounding win for freedom in several states, with the exception of Arizona. There, voters narrowly rejected decriminalization, in no small part due to a massive anti-pot propaganda campaign funded in-part by Big Pharma.

Arizona-based Insys Therapeutics gave $500,000 to a group called Arizonans for Responsible Drug Policy, which amounted to 10 percent of the group's total money used to manufacture and disseminate anti-pot propaganda. Some of the scare tactics Insys used itself was to claim that legalization "fails to protect the safety of Arizona's citizens, and particularly its children," and that production of "narcotic raw materials" promotes abuse.

Both of these claims are patently absurd coming from a pharma corporation under investigation for bribery and marketing fraud relating to its synthetic opioid Subsys — a dead form of fentanyl. As we know, by far the most devastating form of drug abuse – opioid addiction which kills tens of thousand of people a year – was brought about by Big Pharma itself under a legal framework.

The real reason for Insys' opposition to cannabis legalization was spelled out in a 2007 disclosure to the SEC, which stated: "If marijuana or non-synthetic cannabinoids were legalized in the United States…our ability to generate revenue and our business prospects would be materially adversely affected."